California’s revamped stem cell research funding agency had planned to announce its first grants in April, but it has hit a snag with its proposed application review system.
The California Institute for Regenerative Medicine has said its new funding mechanism, CIRM 2.0, will get potentially lifesaving treatments onto the market faster. Researchers and patients will have to wait at least another month to find out if that’s true.
A CIRM spokesman told Research Professional that a planned teleconference to review applications for the first round of CIRM 2.0 awards has proved unworkable. The agency now plans to make its decisions in person at a meeting in May.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.